Akari Therapeutics Plc(AKTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.6M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AKTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Akari Therapeutics Plc (AKTX), a Healthcare sector company. AKTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Akari Therapeutics Plc reports net income of $-14.5M, free cash flow of $-2.5M. Top institutional holders of AKTX by reported 13-F value include ARMISTICE CAPITAL,, Cresset Asset Management,, IFP Advisors,, based on the most recent SEC filings. AKTX trades on the Nasdaq exchange and files with the SEC under CIK 1541157. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Akari Therapeutics Plc directly from SEC EDGAR.
Net Income
Q1 2026
$-14.5M
Free Cash Flow
Q1 2026
$-2.5M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+12.6% YoYOperating Income
+20.2% YoYEPS (Diluted)
Total Assets
-5.3% YoYOp. Cash Flow
+15.8% YoY| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Net Income | $-17.3M +12.6% | $-19.8M |
| Operating Income | $-17.3M +20.2% | $-21.6M |
| EPS (Diluted) | $0.00 | $0.00 |
| Total Assets | $47.9M -5.3% | $50.6M |
| Operating Cash Flow | $-10.6M +15.8% | $-12.6M |
AI Insight: AKTX Financial Trends
Akari's burn rate accelerated sharply in Q1 2026, with operating losses doubling year-over-year despite equity raised.
• Operating loss widened to $16M in Q1 2026 from $4M in Q1 2025; net loss deteriorated to $14M from $4M.
• Equity base fluctuated between $14M–$28M over eight quarters; currently at $14M, lowest since Q2 2024.
• Operating cash outflow remained near $2–$3M per quarter; no material improvement in cash consumption.
⚠ Q1 2026 equity crashed 50% to $14M from $28M at year-end 2025; runway sustainability critical.
⚠ Operating losses accelerating while cash burn stable suggests accrual/non-cash charges mounting—investigate driver.
AI Insight: AKTX Ratio Trends
Akari remains deeply unprofitable with negative returns across all metrics; modest Q2 2025 improvement has stalled.
• ROA improved from -29.8% in Q4 2024 to -14.9% in Q2 2025, then deteriorated to -56.4% in Q3 2025.
• ROIC ranged from -95.0% in Q4 2024 to -45.6% in Q4 2025, showing persistent value destruction.
• ROE worsened to -112.8% in Q3 2025, the worst quarterly result in the available data.
⚠ Q1 2026 data missing; inability to assess current trajectory after sharp Q3 2025 deterioration.
⚠ No profitability or leverage data available; unable to evaluate debt burden or operating efficiency.
Get alerted when AKTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Akari Therapeutics Plc including:
Top Institutional Holders of AKTX
ARMISTICE CAPITAL, LLC
$200.4K38,922 shCresset Asset Management, LLC
$105.9K20,561 shIFP Advisors, Inc
$932.00181 shIFP Advisors, Inc
$877.007,250 shSBI Securities Co., Ltd.
$26.005 shMORGAN STANLEY
$5.001 shTruvestments Capital LLC
$5.001 sh
| Fund | Value | Shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | $200.4K | 38,922 |
| Cresset Asset Management, LLC | $105.9K | 20,561 |
| IFP Advisors, Inc | $932.00 | 181 |
| IFP Advisors, Inc | $877.00 | 7,250 |
| SBI Securities Co., Ltd. | $26.00 | 5 |
| MORGAN STANLEY | $5.00 | 1 |
| Truvestments Capital LLC | $5.00 | 1 |
More Healthcare Companies
View all Healthcare →Put AKTX on your watchlist
Track score changes the day Akari Therapeutics Plc files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AKTX a good stock to buy?
13F Pro's AI-powered analysis of Akari Therapeutics Plc (AKTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AKTX are available on the AKTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AKTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AKTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Akari Therapeutics Plc's investment landscape.